1
|
Palmer V, Djunadi TA, Tantry B, Grigos A. Sepsis Associated With Aggressive Cutaneous Angiosarcoma. Cureus 2024; 16:e55619. [PMID: 38586674 PMCID: PMC10995759 DOI: 10.7759/cureus.55619] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/05/2024] [Indexed: 04/09/2024] Open
Abstract
Cutaneous angiosarcoma is an aggressive tumor most commonly presenting on the head and neck. In this case report, we describe the presentation of sepsis secondary to an aggressive and rapidly expanding wound, located in a sun-protected area on the body, in a patient with multiple concurrent comorbidities. Treatment was tailored toward targeting the causative organisms, as well as identifying the histologic morphology of the pathologic legion. Histopathology and immunohistochemistry were used to confirm the diagnosis of cutaneous angiosarcoma, and the patient-centered decision surrounding palliative chemotherapy is outlined.
Collapse
Affiliation(s)
- Victoria Palmer
- Internal Medicine, Richmond University Medical Center, Staten Island, USA
| | - Trie Arni Djunadi
- Internal Medicine, Richmond University Medical Center, Staten Island, USA
| | - Bhuvana Tantry
- Internal Medicine, Richmond University Medical Center, Staten Island, USA
| | - Angela Grigos
- Internal Medicine, Richmond University Medical Center, Staten Island, USA
| |
Collapse
|
2
|
El Shatanofy M, Thakkar P, Patel V, Joshi A, Goodman J, Siegel R, Haroun F, Ojong-Ntui M, Goyal S, Bauman J, Rao YJ. Intensified Adjuvant Treatment for High-Risk Resected Cutaneous Angiosarcoma of the Head and Neck. Otolaryngol Head Neck Surg 2023; 169:1225-1233. [PMID: 37464928 DOI: 10.1002/ohn.429] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2023] [Revised: 05/10/2023] [Accepted: 05/20/2023] [Indexed: 07/20/2023]
Abstract
OBJECTIVE Previous studies have highlighted the poor survival of patients with cutaneous angiosarcoma of the head and neck. Therapeutic options are limited, and effective treatment strategies are yet to be discovered. The objective of this study is to evaluate overall survival following intensified adjuvant treatment for high-risk resected angiosarcoma of the head and neck. STUDY DESIGN Retrospective observational. SETTING National Cancer Database (NCDB). METHODS Patients diagnosed with nonmetastatic cutaneous angiosarcoma of the head and neck from 2004 to 2016 were identified by NCDB. We retrospectively compared demographics and overall survival between patients who received surgery and radiation therapy (SR) and patients who received surgery and chemoradiation (SRC). The χ2 test, Kaplan-Meier method, and Cox regression models were used to analyze data. RESULTS A total of 249 patients were identified, of which 79.5% were treated with surgery and radiation alone and 20.5% were treated with surgery and chemoradiation. The addition of chemotherapy, regardless of the sequence of administration, was not associated with significantly higher overall survival. Factors associated with worse survival in both groups included positive nodal status and positive margins. Patients with positive nodes had higher overall survival with radiation doses >50.4 Gy compared to ≤50.4 Gy (hazard ratio: 2.93, confidence interval: 1.60-5.36, p < 0.001). CONCLUSION Adjuvant chemotherapy was not significantly associated with higher overall survival for resected nonmetastatic angiosarcoma of the head and neck. Higher radiation doses appear to be prognostic for high-risk diseases.
Collapse
Affiliation(s)
- Muhammad El Shatanofy
- Department of Otolaryngology, The George Washington University Hospital, Washington, District of Columbia, USA
- Department of Otolaryngology, University of Miami Hospital, Miami, Florida, USA
| | - Punam Thakkar
- Department of Otolaryngology, The George Washington University Hospital, Washington, District of Columbia, USA
| | - Vishal Patel
- Department of Dermatology, The George Washington University Hospital, Washington, District of Columbia, USA
| | - Arjun Joshi
- Department of Otolaryngology, The George Washington University Hospital, Washington, District of Columbia, USA
| | - Joseph Goodman
- Department of Otolaryngology, The George Washington University Hospital, Washington, District of Columbia, USA
| | - Robert Siegel
- Department of Hematology Oncology, The George Washington University Hospital, Washington, District of Columbia, USA
| | - Faysal Haroun
- Department of Hematology Oncology, The George Washington University Hospital, Washington, District of Columbia, USA
| | - Martin Ojong-Ntui
- Department of Radiation Oncology, The George Washington University Hospital, Washington, District of Columbia, USA
| | - Sharad Goyal
- Department of Radiation Oncology, The George Washington University Hospital, Washington, District of Columbia, USA
| | - Julie Bauman
- Cancer Center, The George Washington University Hospital, Washington, District of Columbia, USA
| | - Yuan James Rao
- Department of Radiation Oncology, The George Washington University Hospital, Washington, District of Columbia, USA
| |
Collapse
|
3
|
Degnim AC, Siontis BL, Ahmed SK, Hoskin TL, Hieken TJ, Jakub JW, Baum CL, Day C, Schrup SE, Smith L, Carter JM, Sae Kho TM, Glazebrook KN, Vijayasekaran A, Okuno SH, Petersen IA. Trimodality Therapy Improves Disease Control in Radiation-Associated Angiosarcoma of the Breast. Clin Cancer Res 2023; 29:2885-2893. [PMID: 37223927 DOI: 10.1158/1078-0432.ccr-23-0443] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2023] [Revised: 04/07/2023] [Accepted: 05/16/2023] [Indexed: 05/25/2023]
Abstract
PURPOSE To evaluate the impact of trimodality treatment versus monotherapy or dual therapy for radiation-associated angiosarcoma of the breast (RAASB) after prior breast cancer treatment. EXPERIMENTAL DESIGN With Institutional Review Board approval, we identified patients diagnosed with RAASB and abstracted data on disease presentation, treatment, and oncologic outcomes. Trimodality therapy included (i) taxane induction, (ii) concurrent taxane/radiation, and then (iii) surgical resection with wide margins. RESULTS A total of 38 patients (median age 69 years) met inclusion criteria. Sixteen received trimodality therapy and 22 monotherapy/dual therapy. Skin involvement and disease extent were similar in both groups. All trimodality patients required reconstructive procedures for wound closure/coverage, compared with 48% of monotherapy/dual therapy patients (P < 0.001). Twelve of 16 (75%) patients receiving trimodality therapy had a pathologic complete response (pCR). With median follow-up of 5.6 years, none had local recurrence, 1 patient (6%) had distant recurrence, and no patients died. Among 22 patients in the monotherapy/dual therapy group, 10 (45%) had local recurrence, 8 (36%) had distant recurrence, and 7 (32%) died of disease. Trimodality therapy demonstrated significantly better 5-year recurrence-free survival [RFS; 93.8% vs. 42.9%; P = 0.004; HR, 7.6 (95% confidence interval, CI: 1.3-44.2)]. Combining all patients with RAASB regardless of treatment, local recurrence was associated with subsequent distant recurrence (HR, 9.0; P = 0.002); distant recurrence developed in 3 of 28 (11%) patients without local recurrence compared with 6 of 10 (60%) with local recurrence. The trimodality group had more surgical complications that required reoperation or prolonged healing. CONCLUSIONS Trimodality therapy for RAASB was more toxic but is promising, with a high rate of pCR, durable local control, and improved RFS.
Collapse
Affiliation(s)
- Amy C Degnim
- Breast and Melanoma Surgical Oncology, Mayo Clinic, Rochester, Minnesota
| | | | - Safia K Ahmed
- Radiation Oncology, Mayo Clinic, Rochester, Minnesota
| | - Tanya L Hoskin
- Clinical Trials and Biostatistics, Mayo Clinic, Rochester, Minnesota
| | - Tina J Hieken
- Breast and Melanoma Surgical Oncology, Mayo Clinic, Rochester, Minnesota
| | - James W Jakub
- Division of Surgical Oncology, Mayo Clinic, Jacksonville, Florida
| | | | - Courtney Day
- Clinical Trials and Biostatistics, Mayo Clinic, Rochester, Minnesota
| | - Sarah E Schrup
- Mayo Clinic Alix School of Medicine, Mayo Clinic, Rochester, Minnesota
| | - Lauren Smith
- Radiation Oncology, Mayo Clinic, Rochester, Minnesota
| | - Jodi M Carter
- Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota
| | | | | | | | | | | |
Collapse
|
4
|
Guan L, Palmeri M, Groisberg R. Cutaneous angiosarcoma: A review of current evidence for treatment with checkpoint inhibitors. Front Med (Lausanne) 2023; 10:1090168. [PMID: 36993810 PMCID: PMC10040781 DOI: 10.3389/fmed.2023.1090168] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2022] [Accepted: 02/21/2023] [Indexed: 03/14/2023] Open
Abstract
Cutaneous angiosarcoma (cAS) is a rare and aggressive subtype of soft tissue sarcoma with poor prognosis and suboptimal treatment options. Clinical presentation is variable, but cAS often arises from the head and neck. The most widely accepted current approach, surgical excision with adjuvant radiotherapy, is associated with high recurrence rates and can leave patients with profound disfigurement. Chemotherapy and targeted therapy alternatives have had limited success. Thus, there is a significant unmet need to address the absence of durable treatments for advanced and metastatic cAS. Like melanoma and cutaneous squamous cell carcinoma, tumor types with known response to immunotherapy, cAS harbors immune biomarkers, such as tumor mutational burden high (TMB-H), PD-L1 positivity, ultraviolet signature expression, and tertiary lymphoid structures. While data on the use and efficacy of immunotherapy in cAS is limited, the biomarkers suggest a promising advancement in future treatment options. This review aims to summarize and discuss current data from case reports, case series, retrospective studies and clinical trials regarding immunotherapy treatment and outcomes for cAS.
Collapse
|
5
|
Tani M, Nagahara A, Takada S, Fujita K, Fukuhara S, Uemura M, Kiuchi H, Imamura R, Nonomura N. A case of mediastinal teratoma with malignant transformation into angiosarcoma and relapse with multiple bone metastases that was cured by a multidisciplinary treatment. IJU Case Rep 2023; 6:93-96. [PMID: 36874996 PMCID: PMC9978083 DOI: 10.1002/iju5.12551] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2022] [Accepted: 10/25/2022] [Indexed: 11/13/2022] Open
Abstract
Introduction Complete resection is essential for the treatment of teratoma with malignant transformation, and if metastasis occurs, it will be difficult to cure. We report a case of primary mediastinal teratoma with differentiation into angiosarcoma that caused bone metastases but was cured by multidisciplinary treatment. Case presentation A 31-year-old man with a primary mediastinal germ cell tumor underwent primary chemotherapy followed by post-chemotherapy resection, with angiosarcoma due to malignant transformation found in the surgical specimen. Femoral diaphyseal metastasis was manifested, and he underwent femur curettage followed by radiation therapy of 60 Gy in parallel with 4 cycles of chemotherapy combining gemcitabine and docetaxel. Although thoracic vertebral bone metastasis emerged 5 months after treatment, intensity-modulated radiation therapy was successful, and metastatic lesions have remained shrunken for 39 months after treatment. Conclusion Even if complete resection is difficult, teratoma with malignant transformation may be cured by multidisciplinary treatment based on histopathology.
Collapse
Affiliation(s)
- Masaru Tani
- Department of Urology Osaka University Graduate School of Medicine Suita Osaka Japan
| | - Akira Nagahara
- Department of Urology Osaka University Graduate School of Medicine Suita Osaka Japan
| | - Shingo Takada
- Department of Urology Osaka Police Hospital Osaka Japan
| | - Kazutoshi Fujita
- Department of Urology Osaka University Graduate School of Medicine Suita Osaka Japan
| | - Shinichiro Fukuhara
- Department of Urology Osaka University Graduate School of Medicine Suita Osaka Japan
| | - Motohide Uemura
- Department of Urology Osaka University Graduate School of Medicine Suita Osaka Japan
| | - Hiroshi Kiuchi
- Department of Urology Osaka University Graduate School of Medicine Suita Osaka Japan
| | - Ryoichi Imamura
- Department of Urology Osaka University Graduate School of Medicine Suita Osaka Japan
| | - Norio Nonomura
- Department of Urology Osaka University Graduate School of Medicine Suita Osaka Japan
| |
Collapse
|
6
|
Messias H, Martins M, Zagalo C, Gomes P. Multifocal cutaneous angiosarcoma of the scalp—A challenging reconstructive case managed with skin substitutes. Cancer Rep (Hoboken) 2022; 5:e1659. [PMID: 35819124 PMCID: PMC9575495 DOI: 10.1002/cnr2.1659] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2022] [Revised: 05/10/2022] [Accepted: 05/19/2022] [Indexed: 11/26/2022] Open
Abstract
Background Cutaneous angiosarcoma (AS) of the head and neck is a rare highly aggressive tumor, often associated with difficult local control of the disease and poor prognosis. This article describes a case of multifocal cutaneous AS of the scalp, mainly addressing its difficult surgical management and challenging reconstruction and concludes with a review of the literature. Methods A 70‐year‐old Caucasian male was referred to our hospital with a growing scalp lesion initially suspected to be benign, but later diagnosed with AS. Results The patient had tumor recurrence and a difficult reconstruction for which dermal substitutes proved very useful. Conclusion AS can mimic a benign lesion in its early stages. Skin substitutes, namely dermal templates, can be useful to meet the complex needs of reconstruction and oncological surveillance of patients with AS.
Collapse
Affiliation(s)
- Henrique Messias
- Head and Neck Surgery Department Portuguese Institute of Oncology Francisco Gentil Lisbon Portugal
- Division of Health Sciences University of Edinburgh Edinburgh United Kingdom
| | - Mariluz Martins
- Head and Neck Surgery Department Portuguese Institute of Oncology Francisco Gentil Lisbon Portugal
| | - Carlos Zagalo
- Head and Neck Surgery Department Portuguese Institute of Oncology Francisco Gentil Lisbon Portugal
| | - Pedro Gomes
- Head and Neck Surgery Department Portuguese Institute of Oncology Francisco Gentil Lisbon Portugal
| |
Collapse
|
7
|
Abstract
OPINION STATEMENT Cutaneous angiosarcoma is a rare and invasive malignant tumor. For localized cAS patients, wide-margin excision was recommended. Due to the latent local invasion characteristic of cAS, we suggest preoperative and postoperative radiotherapy to nearly all patients. Recently, there is growing interest in using neoadjuvant chemotherapy and/or radiotherapy as part of a combination therapy regimen, which may allow some patients to undergo potentially less disabling surgery. For metastatic cAS patients with unresectable tumors and who refuse surgery, radical radiotherapy or chemoradiotherapy may be an option. Paclitaxel was recognized as the first-line treatment. For tumors resistant to taxanes, emerging medications such as targeted agents and immunotherapy are also under investigation.
Collapse
|
8
|
Current Management of Angiosarcoma: Recent Advances and Lessons From the Past. Curr Treat Options Oncol 2021; 22:61. [PMID: 34097172 DOI: 10.1007/s11864-021-00858-9] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/31/2021] [Indexed: 01/18/2023]
Abstract
OPINION STATEMENT Despite their rarity, angiosarcomas are one of the most aggressive soft tissue sarcomas. Management can often be challenging due to their location and infiltrative nature. A multidisciplinary treatment approach is always warranted, but the recurrence remains high even for localized tumors despite multimodality treatment. In the metastatic setting, cytotoxic chemotherapies, targeted therapies, and, more recently, immunotherapy are used. The sequence of systemic therapies remains currently a topic of active investigation. Over the last couple of years, there have been significant advances in understanding angiosarcoma biology, most notably via patient-driven initiatives like the Angiosarcoma Project. The knowledge derived from such translational work has led to identifying potential biomarkers of response to treatments and exploring new therapeutic avenues. More clinical trials are underway to expand treatment options and improve patient outcomes.
Collapse
|